Versatility of the Curcumin Scaffold: Discovery of Potent and Balanced Dual BACE-1 and GSK-3β Inhibitors
Rita Maria Concetta Di Martino(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Federica Belluti(University of Bologna), Andrea Cavalli(Italian Institute of Technology), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Angela Rampa(University of Bologna), Paola Bisignano(Vanderbilt University), Alessandra Bisi(University of Bologna), Silvia Gobbi(University of Bologna), Angela De Simone(University of Turin), Vincenza Andrisano(University of Bologna), Giovanni Bottegoni(University of Urbino), Daniel I. Pérez(Cedars-Sinai Medical Center), Christian Bergamini(University of Bologna), Romana Fato(University of Bologna)
Cited by 123
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
Deuterium in drug discovery: progress, opportunities and challenges
|Nature Reviews Drug Discovery|2023|458
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334